Diabetes
Intact Proinsulin EIA: is a two-site enzyme-immunoassay (EIA), employing a specific solid phase antibody immobilised on microtitre wells and a soluble antibody labelled with biotin. With results in 4 hours, the assay is easy to use and features high specificity (no cross reactivity with split proinsulins, insulin or c-peptide) and sensitivity, with a limit of detection of 0.3 pmol/L. The Lab21 assay utilises monoclonal antibodies to minimise the cross reactivity with split proinsulins that other assay have historically suffered with.

Intact Proinsulin CLIA: a chemiluminecent test for the quantification of the major precursor molecules (intact proinsulin, 31-32, 32-33, 64-65 and 65-66 split proinsulins) produced during insulin biosynthesis in the blood. In patients with type 2 diabetes, relatively greater proportions of intact proinsulin, 32-33 split proinsulin and des 31-32 split proinsulin find their way into peripheral blood. Only small amount of unmodified proinsulin finds its way into the circulation in normal subjects.

Intact Proinsulin EIA: a two-site enzyme-immunoassay (EIA), employing a specific solid phase antibody immobilised on microtitre wells and a soluble antibody labelled with biotin. With results in 4 hours, the assay is easy to use and features high specificity (no cross reactivity with split proinsulins, insulin or c-peptide) and sensitivity, with a limit of detection of 0.3 pmol/L. The Lab21 assay utilises monoclonal antibodies to minimise the cross reactivity with split proinsulins that other assay have historically suffered with.

C-Peptide CLIA: a two-site immunoassay, employing a C-peptide-specific solid phase antibody immobilised on microtitre wells, and a soluble antibody labelled with a chemiluminescent acridinium ester. With results in under 3 hours, the assay is easy to use and features high specificity (negligible cross reactivity with insulin (0%) or c-peptide (2%)), a high sensitivity (5 pmol/L) and a wide working range, 0-6000 pmol/L, reducing the need for regular sample dilution.

Insulin CLIA: a two-site immunoassay, employing an insulin-specific solid phase antibody immobilised on microtitre wells, and a soluble antibody labelled with a chemiluminescent acridinium ester. With results in under 3 hours, the assay is easy to use and features high specificity (negligible cross reactivity with intact proinsulin, 32-33 split proinsulin and des 31-32 split proinsulin) making it ideal for determining HOMA scores. Therapeutic insulin analogues can be measured using this assay.

Click here to view our diabetes page


Other hormone EIA Tests:

Cortisol: Indication: Adrenocortical insufficiency (Addison´s disease), Cushing´s syndrome, Growth disturbance in children. Quantitative determination of Cortisol in human serum or plasma. Reaction: 60/15 min, 450nm, 37°C/RT.

DHEA-S: Indication: Adrenal hyperplasia, differential diagnosis of hirsutism. Quantitative determination of DHEA-S (Dehydroepiandrosterone sulphate) in human serum or plasma. Reaction: 60/15 min, 450nm, 37°C/RT.

Progesterone: Indication: Hypothalamic pituitary insufficiency, gonadal insufficiency. Quantitative determination of Progesterone in human serum or plasma.
Reaction: 60/15 min, 450nm, 37°C/RT.

Testosterone: Indication: Hirsutism, virilisation, ovarian tumours, hypothalamic pituitary unit diseases, testicular tumours, prostate cancer, hypopituitarism, Klinefelter´s syndrome, testicular feminisation, orchidectomy. Quantitative determination of Testosterone in human serum or plasma.
Reaction: 60/15 min, 450nm, 37°C/RT.

17-Beta Estradiol: Indication: Evaluation of ovarian functions. Quantitative determination of 17-ß Estradiol in human serum or plasma. Reaction: 120/30 min, 450nm, 37°C/RT.

T3: Indication: Hyper- or Hypo-Thyroidism. Quantitative determination of T3 (Total Triiodothyronine) in human serum. Reaction: 60/15 min, 450nm, RT.

FT3: Indication: Hyper- or Hypo-Thyroidism. Quantitative determination of FT3 (Free Triiodothyronine) in human serum. Reaction: 60/15 min, 450nm and 620/630 nm, RT.

T4: Indication: Hyper- or Hypo-Thyroidism. Quantitative determination of T4 (Total Thyroxine) in human serum or plasma. Reaction: 60/15 min, 450-620nm, RT.

FT4: Indication: Hyper- or Hypo-Thyroidism. Quantitative determination of FT4 (Free Thyroxine) in human serum. Reaction: 60/15 min, 450nm and 620/630 nm, RT.

TSH: Indication: Hypothyroidism, hypothalamic abnormalities. Quantitative determination of TSH (Thyroid stimulating hormone, thyrotropin) in human serum or plasma.
Reaction: 60/60/20 min, 450nm and 620nm, RT.

hCG: Indication: Early detection of pregnancy, chorion epithelioma and embryonic cell carcinoma. Quantitative determination of ß-hCG (human chorionic gonadotropin ß-chain) in human serum or plasma. Reaction: 30/30/15 min, 450nm, RT.

hGH: Indication: Hypothalamic pituitary retarded excessive growth, hypothalamic pituitary dwarfism or gigantism quantitative determination of hGH (human growth hormone) in human serum.
Reaction: 60/15 min, 450 nm, RT.

Prolactin: Indication: Disease of the human breast, corpus luteum insufficiency, female sterility, hypothalamic pituitary diseases. Quantitative determination of Prolactin in human serum or plasma.
Reaction: 30/30/15 min, 450-620nm, RT.

FSH: Indication: Gonadal insufficiency, hypothalamic pituitary insufficiency. Quantitative determination of FSH (follicle stimulating hormone) in human serum or plasma. Reaction: 60/10 min, 450nm, RT.

LH: Indication: Gonadal insufficiency, hypothalamic pituitary insufficiency. Quantitative determination of LH (Luteinising hormone, lutropin) in human serum or plasma. Reaction: 60/15 min, 450nm, RT.


Products available: